<DOC>
	<DOCNO>NCT00060801</DOCNO>
	<brief_summary>The purpose study determine effect 24 week treatment BIIL 284 BS compare placebo pulmonary function incidence pulmonary exacerbation adult pediatric cystic fibrosis patient .</brief_summary>
	<brief_title>Efficacy Safety 24 Weeks Oral Treatment With BIIL 284 BS Adult Pediatric Patients</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>INCLUSION CRITERIA : Male female patient &gt; = 6 year pediatric 617 year inclusive ; adult &gt; = 18 year ) Body weight &gt; = 20 kg ( determined Visit 1 ) Confirmed diagnosis CF Able perform acceptable spirometric maneuver , accord American Thoracic Society standard . FEV1 2585 % predict Clinically stable The patient patient 's legally acceptable representative must able give informed consent . The patient must able swallow BIIL 284 BS tablet whole . Patients take chronic medication must willing continue therapy entire duration study . EXCLUSION CRITERIA : Patients significant history allergy/hypersensitivity ( include medication allergy ) deem relevant trial judge Investigator . `` Relevance '' context refers increase risk hypersensitivity reaction trial medication ; specific issue concern currently identify respect use BIIL 284 BS allergic patient per se . Patients participate another study Investigational drug within one month 6 halflives ( whichever great ) precede screen visit . Patients know relevant substance abuse , include alcohol drug abuse . Female patient pregnant lactating , include female positive serum pregnancy test screening ( pregnancy test perform female child bear potential ) . Female patient child bear potential use medically approve form contraception . Patients unable comply food requirement prior dose . Patients document persistent colonization Burkholderia cepacia . Patients chronically use oral corticosteroid highdose ibuprofen . Patients hemoglobin &lt; 9.0 g/dL ; platelet &lt; 100x10 9th power/L ; SGOT ( ALT ) SGPT ( AST ) &gt; 2.5 time upper limit normal ; creatinine &gt; 1.5 time upper limit normal . Clinically significant disease medical condition Cystic Fibrosis Cystic Fibrosisrelated condition , opinion Investigator , would compromise safety patient quality data .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>BIIL 284</keyword>
	<keyword>Boehringer Ingelheim</keyword>
</DOC>